Modified Poxvirus Oncolytic Vectors Reducing Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The injection of high doses of Poxviruses to achieve an antitumoral effect raises toxicity issues, with adverse reactions such as fever, headache, and skin reactions, necessitating the development of safer Poxviruses with equivalent oncolytic activity.
Innovation Solution
Poxviruses with defective I4L and/or F4L genes are developed, which have an improved safety profile while maintaining equivalent oncolytic activity compared to their natural counterparts, utilizing recombinant techniques to modify the viral genome and introduce therapeutic genes or suicide genes for targeted cancer therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If high doses of Poxviruses are injected to achieve antitumoral effect, then oncolytic activity is improved, but toxicity and adverse reactions worsen
Solution Approach 1:
The patent modifies the viral genome by deleting specific genes (I4L and/or F4L) to change the virus's parameters, resulting in reduced toxicity while maintaining oncolytic activity. This genetic modification alters the virus's interaction with host cells, achieving the desired balance between efficacy and safety.
Solution Approach 2:
The patent extracts or removes specific viral genes (I4L and/or F4L) that are responsible for causing toxicity and adverse reactions. By taking out these problematic genetic elements while retaining other essential viral functions, the patent achieves reduced toxicity without compromising the virus's ability to infect and kill cancer cells.
2Productivity
If high doses of Poxviruses are injected to achieve antitumoral effect, then oncolytic activity is improved, but adverse reactions worsen
Solution Approach 1:
The patent changes the viral parameters by deleting specific genes (I4L and/or F4L), which modifies the virus's biological characteristics. This genetic alteration reduces the generation of harmful factors such as fever, headache, and skin reactions while preserving the virus's oncolytic function.
Solution Approach 2:
The patent extracts harmful genetic elements (I4L and/or F4L genes) from the viral genome that are responsible for causing adverse reactions. By removing these specific genes while maintaining other essential viral functions, the patent achieves reduced adverse reactions without compromising tumor-killing efficacy.
Data Source
AI summary
The present invention relates to a poxvirus comprising a defective F4L and/or I4L gene, to composition comprising such poxvirus and to the methods and use of such compositions and poxviruses for therapeutic purposes, and more particularly for the treatment of cancer.